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acubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor that simultaneously blocks the renin-angiotensin-aldosterone system and augments several endogenous vasoactive peptides. 1 In PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/valsartan reduced the primary composite outcome of cardiovascular death or heart failure hospitalization compared with enalapril in patients with symptomatic heart failure with reduced ejection fraction. 2 Sacubitril/valsartan lowers blood pressure, 3 and in heart failure patients treated in PARADIGM-HF, participants randomized to sacubitril/valsartan experienced more symptomatic hypotension compared with those taking enalapril although there were no differences between groups in rates of study medication discontinuation because of hypotension. 2 Nevertheless, concerns on hypotension, which was the most frequently observed side-effect in the sacubitril/valsartan arm of PARADIGM-HF, may represent an impediment to more widespread use of sacubitril/valsartan in patients with heart failure and reduced ejection fraction despite recent American College of Cardiology/American Heart Association/Heart Failure Society of America guidelines that support its use in appropriate patients. 4 Moreover, because PARADIGM-HF included an active run-in period, patients more prone to hypotension may have dropped out of the study before randomization. Thus, to inform clinicians who may use sacubitril/valsartan in a wide variety of patients, we sought to characterize hypotensive episodes during both the run-in period and after randomization, assess characteristics associated with hypotension, actions taken, and the influence of hypotension on efficacy of sacubitril/valsartan relative to enalapril.
METHODS Patients
The PARADIGM-HF study enrolled patients with symptomatic heart failure with reduced ejection fraction (≤40%) and mild elevation in natriuretic peptides. The protocol was approved at each participating site by an ethics committee or institutional review board. All participants provided written informed consent in accordance with established guidelines for the protection of human subjects. Patients had to tolerate enalapril 10 mg daily (or equivalent dose of another angiotensin-converting enzyme [ACE] inhibitor or angiotensin receptor blocker [ARB]) for at least 1 month before study enrollment and have a systolic blood pressure ≥100 mm Hg at screening. Participants underwent sequential single-blind run-in periods, first with enalapril, titrated to 10 mg twice daily, and subsequently with sacubitril/valsartan, initiated at 100 mg bid (49/51 mg bid) and titrated to 200 mg (97/103 mg) twice daily. Patients with a systolic blood pressure of ≥95 mm Hg and tolerating the enalapril run-in period proceeded to the sacubitril/valsartan runin, and those tolerating both with a systolic blood pressure ≥95 mm Hg were randomized to either enalapril, 10 mg twice daily, or sacubitril/valsartan 200 mg (97/103 mg) twice daily. During the sacubitril/valsartan run-in phase, investigators were encouraged to first attempt to adjust doses of nonlife saving blood pressure-lowering agents (calcium channel blockers, α-blockers, and nitrates) if hypotension occurred. During the double-blind study phase, investigators were encouraged to treat hypovolemia and adjust other blood pressure-lowering agents first before downtitrating study dose levels or potentially temporarily discontinuing study medication. The details of the study design have been published previously.
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Assessment of Hypotensive Events
Investigator reported symptomatic hypotension as an adverse event on case report forms via a checkbox, which were assessed during run-in and postrandomization study periods, at each study visit. Investigators were asked to query participants for symptomatic hypotension by asking the following: Since the last protocol visit, has the patient experienced any of the following new or worsening adverse events? Actions taken in response to a hypotension adverse event were at the discretion of site investigators and could include no action, dose reduction or temporary interruption of study
WHAT IS NEW?
• Among patients with heart failure with reduced ejection fraction, treatment with sacubitril/valsartan resulted in more hypotension relative to enalapril but did not lead to higher rates of study drug discontinuation.
• The likelihood of hypotension was increased among individuals of older age, those with lower systolic blood pressure at screening, and patients taking lower doses of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers before study enrollment.
• Hypotension was associated with an increased risk for cardiovascular mortality or heart failure hospitalization; however, hypotension did not affect the relative efficacy of sacubitril/valsartan compared with enalapril on these clinical events.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Most patients who tolerate robust doses of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are also likely to tolerate sacubitril/valsartan. • Hypotension does not lessen the treatment advantage of sacubitril/valsartan over enalapril.
• Patients of older age with lower blood pressure require more intense monitoring when switching between blockers of the renin-angiotensin-aldosterone system. medication, permanent discontinuation of study medication, dose adjustment of concomitant medications, use of nondrug interventions, hospitalization, or a combination of the above.
Statistical Analysis
Participants with hypotensive events were counted separately during each run-in phase and post-randomization. Baseline characteristics between those with and without hypotensive events during run-in or post-randomization were compared using t tests for continuous data and χ 2 tests for categorical data. Predictors of hypotension post-randomization were investigated using multivariable logistic regression, adjusting for baseline characteristics at time of randomization as follows: age, sex, race, region, body mass index, New York Heart Association functional class, left ventricular ejection fraction, ischemic cardiomyopathy, prior heart failure hospitalization, history of hypertension, diabetes mellitus, myocardial infarction, stroke, atrial fibrillation, systolic blood pressure, heart rate, presence of implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy, prior use of ACE inhibitor or ARB, and current use of diuretics, β-blockers, mineralocorticoid receptor antagonists, digoxin, and baseline serum creatinine, and N-terminal pro-B-type natriuretic peptide (log transformed). The effect of hypotension during run-in and post-randomization on the efficacy of sacubitril/valsartan relative to enalapril for the primary outcome (cardiovascular death or heart failure hospitalization) and for mortality were estimated using Cox regression models with hypotension as a time-updated variable. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
RESULTS
The flow of patients and disposition of those experiencing hypotension during the study are shown in Figure 1 . Overall, PARADIGM-HF enrolled 10 521 patients, of whom 10 513 entered the enalapril run-in period. During the enalapril run-in phase, 136/10 513 (1.3%) participants experienced hypotension, 43 (32%) entered the sacubitril/valsartan run-in period and 93 did not. Of the 43 who experienced hypotension during enalapril run-in who continued to the sacubitril/ valsartan run-in, 6 (14%) had hypotension. Of the 9419 participants who entered the sacubitril/valsartan run-in period, 228 (2.4%) experienced hypotension. Of those experiencing hypotension, 112 (49%) participants were ultimately randomized. The majority of participants who had hypotension in the enalapril run-in period experienced this when titrated to 10 mg twice daily. During the sacubitril/valsartan run-in period, hypotension was equally split between the 100 and 200 mg doses. Of participants who tolerated enalapril run-in without hypotension, the incidence of a hypotensive event during sacubitril/valsartan run-in period was 2.4%.
Characteristics of participants at screening (prerun-in) visit who experienced hypotension during the trial are shown in Table 1 . Those who experienced hypotension were older, had lower systolic and diastolic blood pressures at screening, lower estimated glomerular filtration rate, lower left ventricular ejection fraction, higher N-terminal pro-B-type natriuretic peptide, and were more likely to be taking ACE inhibitors, nitrates, calcium channel blockers, statins, and oral anticoagulants. They were also more likely to be from the North American or Western European regions and more likely to have a history of ischemia-related events (coronary heart disease, coronary artery bypass grafting, unstable angina) and implanted cardiac resynchronization therapy or ICD therapy. Randomization visit characteristics associated with hypotension post-randomization included lower systolic blood pressure, older age, receipt of an ICD device, hypertension, atrial fibrillation, diabetes mellitus (among those randomized to take enalapril), creatinine, and North American region (Table 2) . Although the likelihood of having hypotension during run-in was low, participants who were on subtarget doses of ACE inhibitors (less than enalapril 10 mg twice daily or equivalent) or ARBs (less than valsartan 160 mg twice daily or equivalent) before screening had a higher risk of hypotension (4% versus 3%; P=0.005).
Approximately two thirds of participants who experienced hypotension during the enalapril run-in phase dropped out of the trial at that point, and approximately half the participants who experienced hypotension during the sacubitril/valsartan run-in period dropped out of the study before randomization. After randomization, hypotensive episodes were more common in those assigned to sacubitril/valsartan: 388 (9.2%) participants experienced 501 hypotensive events in the enalapril arm, whereas 588 (14.0%) participants experienced 803 hypotensive events in the sacubitril/ valsartan arm. Changes in systolic blood pressure from the time of screening to the visit during which hypotension was reported (when available), or the study visit after the report of hypotension were −13±18 mm Hg for enalapril and −17±18 mm Hg for sacubitril/valsartan (P=0.001). Systolic blood pressure values at the time of hypotension were 108±18 mm Hg among those taking enalapril compared with 106±18 mm Hg (P=0.07).
Although all actions taken for hypotension occurred more frequently in the sacubitril/valsartan arm (consistent with the increased number of overall events), the proportions of events that were addressed by specific actions were similar between the 2 treatment arms ( Table 3 ). The majority of participants who experienced hypotension after randomization underwent a dose reduction or temporary disruption of study medication and a small number required permanent study drug discontinuation (Table 3 ). The frequency of dose reduction or temporary study drug interruption because of hypotension was similar in both treatment arms (51.7% for enalapril, 54.1% for sacubitril/valsartan; P=0.42). Permanent study medication discontinuation rates were similar in both treatment arms. Changes in concomitant medications were made in 12% to 13% of participants and did not differ by treatment arm. Hospitalization rates because of hypotension were similar between treatment arms (7.4% for enalapril, 5.6% for sacubitril/valsartan; P=0.23). Deaths were more frequent after hypotension events in the enalapril group compared with the sacubitril/valsartan group at 15 days post-event (8.2% versus 5.6%), 30 days (12.5% versus 8.0%), and 90 days (22.5% versus 12.8%; P=0.003). Individuals who experienced hypotension during the run-in phase and continued to randomization benefited from sacubitril/valsartan to a similar extent with respect to the primary outcome as those who did not experience a hypotensive episode during the run-in period (Figure 2 ; P interaction=0.76). After randomization, hypotension was associated with an increased risk for the primary outcome (hazard ratio, 2.63 [95% confidence interval, 2.21, 3.13]). However, the prognostic importance of this association (Figure 3 ; P interaction=0.011).
DISCUSSION
We found that in patients with heart failure and reduced ejection fraction enrolled in PARADIGM-HF, hypotensive events occurred in 1.3% of patients during the enalapril run-in and in 2.4% of patients during the sacubitril/valsartan run-in. Among patients who did not have hypotension during enalapril run-in, the incidence of hypotension when receiving sacubitril/valsartan was 2.4%. After randomization, patients were also more likely to experience hypotension if randomized to sacubitril/valsartan. Individuals who experienced a hypotensive event, regardless of treatment assignment, were older, had lower systolic blood pressure at screening, and had ICDs. The likelihood of having hypotension during run-in was higher in patients who were on subtarget doses of ACE inhibitors or ARBs before screening. Patients who experienced hypotension during run-in and were subsequently randomized derived the same benefit from sacubitril/valsartan relative to enalapril on the primary outcome as those without hypotension. Hypotension that occurred post-randomization was associated with an increased risk for the primary outcome, which was more evident among those taking enalapril.
Of the major adverse events of interest reported in the original PARADIGM-HF report, hypotension was the only one statistically more frequent in patients receiving sacubitril/valsartan compared with those assigned to receive enalapril, although there was no differential discontinuation of study drug because of hypotension, nor differences in hypotension reported as serious adverse events or hospitalizations because of hypotension. Sacubitril/valsartan has been shown to lower blood pressure in patients with hypertension. 3 In PARADIGM-HF, the overall systolic blood pressure difference between the sacubitril/valsartan and enalapril arms was 2.7 mm Hg. Hypotension occurred relatively infrequently during both run-in periods (<5% of patients total) although somewhat more during sacubitril/valsartan run-in; nevertheless, these small numbers of hypotension events suggest that the vast majority of patients who tolerate full-dose ACE inhibition will also tolerate sacubitril/valsartan.
The frequency of hypotension during the run in and double-blind phases of PARADIGM-HF is consistent with previous studies of renin-angiotensin-aldosterone system inhibitors in patients with heart failure with reduced ejection fraction. In SOLVD (Studies of Left Ventricular Dysfunction), which examined enalapril versus placebo in patients with symptomatic heart failure with reduced ejection fraction or asymptomatic patients with left ventricular dysfunction, participants underwent a 2-to 7-day drug challenge phase before randomization to ensure tolerability of enalapril, dosed at 2.5 mg twice daily. During this phase, dizziness and lightheadedness attributed to hypotension occurred in 2.2% of participants. 6 In the double-blind phase, dizziness or faintness attributable to hypotension occurred in 14.8% of those randomized to enalapril compared with 7.1% in the placebo group. 7 In CONSENSUS (Cooperative North Scandinavian Enalapril Survival Study), investigating enalapril versus placebo in patients with severe heart failure symptoms, dropout because of hypotension occurred at a rate of 11% when the starting dose was 5 mg twice daily and decreased to 3% when the starting dose was lowered to 2.5 mg twice daily. 8 Participants enrolled in the CARMEN study (The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation) were randomized to uptitration of enalapril, carvedilol, or both; hypotension occurred in 4%, 6%, and 11% of participants, respectively. 9 Thus, hypotension rates in PARA-DIGM-HF were not higher despite presence of additional blood pressure-lowering medications per contemporary heart failure guidelines, including β-blockers and mineralocorticoid receptor antagonists.
We found several factors that were associated with hypotension in both groups post-randomization, including older age, lower systolic blood pressure, and receipt of an ICD. These findings corroborate previous investigations of hypotension with renin-angiotensinaldosterone system blockers. In the HEAAL study (Heart Failure Endpoint Evaluation of Angiotensin II Antagonist Losartan), losartan 150 mg significantly reduced the risk of major heart failure events compared with losartan 50 mg but was associated with more hypotension. 10 In an analysis investigating potential predictors of hypotension in the HEAAL study older age, lower systolic blood pressure, and use of mineralocorticoid receptor antagonists were associated with hypotension. 11 In the SOLVD trial, hypotension was the most common cause of study medication discontinuation, and lower baseline blood pressure was also associated with a higher risk for developing hypotension. 7 In ValHeFT (Valsartan Heart Failure Trial), systolic blood pressure <110 mm Hg was more frequently associated with study medication discontinuations, specifically in the valsartan treatment group. 12 A higher dose of lisinopril was associated with more hypotension in the ATLAS trial (Assessment of Treatment With Lisinopril and Survival) compared with low dose lisinopril, a finding that was more pronounced among older patients with lower baseline blood pressure and elevated serum creatinine, although events deemed to be serious or that led to study drug discontinuations were infrequent. 13, 14 In PARADIGM-HF, we found that characteristics that were indicative of more advanced heart disease, such as use of ICDs, was also associated with more frequent hypotension.
Concern about hypotension has emerged as one of the key barriers to broader adoption of sacubitril/valsartan, which has now been endorsed by the US American College of Cardiology/American Heart Association/Heart Failure Society of America and European Society of Cardiology guidelines as a class I indication, 4, 15, 16 with the US guidelines advocating switching patients with New York Heart Association functional class II or III heart failure with reduced ejection fraction who tolerate ACE inhibitors or ARBs to sacubitril/valsartan. 4 We found that patients who had hypotension during the run-in period who were subsequently randomized derived similar benefit from sacubitril/valsartan relative to enalapril as those who did not have these events. Likewise, we previously observed that low systolic blood pressure during run-in and postrandomization did not attenuate the benefit of sacubitril/ valsartan compared with enalapril. 17 These data underscore the importance of strategies to minimize the risk of hypotension during titration, including ensuring that patients are started on the appropriate dose of sacubitril/valsartan. Moreover, we have previously found that patients who cannot tolerate target doses of sacubitril/ valsartan and are downtitrated to lower doses still receive a greater benefit compared with those who are downtitrated to lower doses of enalapril. 18 Because the factors that influence hypotension are similar in patients receiving sacubitril/valsartan and individuals receiving enalapril, these data would suggest that patients who may not tolerate a full dose of sacubitril/valsartan would also not likely tolerate full-dose enalapril and would still derive benefit from the lower dose of sacubitril/valsartan. Overdiuresis is another factor that may lead to hypotension in patients with heart failure, and in an analysis of PARADIGM-HF, participants taking sacubitril/valsartan exhibited more loop diuretic dose reductions and less frequent dose increases compared with individuals randomized to enalapril. 19 As such, patients first initiated on sacubitril/valsartan may benefit from an assessment of their loop diuretic dose both at baseline and shortly after initiating treatment. If hypotension occurs after initiation of sacubitril/valsartan, clinicians may consider decreasing doses of nonessential vasodilators first, followed by reducing loop diuretic doses if appropriate. Last, downtitration of sacubitril/valsartan may reduce symptoms related to hypotension.
Several limitations of this analysis should be noted. This was a post hoc investigation of the PARADIGM-HF study that was not prespecified, thus data require cautious interpretation. We relied on investigator reported hypotension, which could have been incompletely captured or documented and may have lacked precision. The sequential run-in design of the PARADIGM-HF study was such that participants who did not tolerate the enalapril run-in did not progress to the sacubitril/valsartan run-in phase, which limited the ability to more completely capture hypotension during the sacubitril/valsartan run-in phase. In addition, rates of hypotension observed may not be representative of hypotension that could occur in patients with differing characteristics from those enrolled in the study. Expanded use of sacubitril/valsartan and more real world experience will better inform the frequency of hypotension with this drug and potential factors that may prevent it.
In summary, we found that hypotension was more common with sacubitril/valsartan than enalapril both in run-in and after randomization but did not differentially affect permanent discontinuations of study drug. Fewer than 5% of patients who tolerated full-dose enalapril experienced hypotension when exposed to sacubitril/valsartan. Nevertheless, patients who continued to randomization after hypotension still derived greater benefit from sacubitril/valsartan than enalapril. These data suggest that most patients with heart failure who are able to tolerate target doses of ACE inhibitors will also be able to tolerate sacubitril/valsartan and that older patients with more severe heart failure may require more intense monitoring when titrating or switching between RAAS blockers. Figure 3 . Kaplan-Meier curves showing death after hypotension events by treatment assignment. Individuals taking sacubitril/valsartan had fewer events compared with the enalapril group. AE indicates adverse event.
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